Nadofaragene Firadenovec: Adding to the Treatment Regimen Protocol – Joshua Meeks
Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA approval for nadofaragene, noting patient interest in new treatment options. Dr. Meeks outlines the challenges with current therapies, including dual chemotherapy and Pembrolizumab, and points to nadofaragene’s…